• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/10/21 11:15:27 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email
    SC 13G/A 1 wf_cyanotechc-232437301x.htm







    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 10)

    CYANOTECH CORP

    (Name of Issuer)

    COM PAR $0.02

    (Title of Class of Securities)

    232437301

    (CUSIP Number)

    February 28, 2021

    (Date of Event Which Requires Filing of this Statement)
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]Rule 13d-1(b)
    []Rule 13d-1(c)
    []Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 232437301

    Person 1
     1.(a) Names of Reporting Persons.
    Wells Fargo & Company
     (b) Tax ID
    41-0449260

     2.Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)  []
      (b)  []

     3.SEC Use Only . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

     4.Citizenship or Place of Organization   Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    5. Sole Voting Power 18

    6.  Shared Voting Power 0

    7. Sole Dispositive Power 18

    8. Shared Dispositive Power 0


    9.Aggregate Amount Beneficially Owned by Each Reporting Person 18


    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)


    11. Percent of Class Represented by Amount in Row (9)  0.00 %


    12. Type of Reporting Person (See Instructions)

    HC

    Item 1.
     (a)Name of Issuer
    CYANOTECH CORP
     (b)Address of Issuer's Principal Executive Offices
      73-4460 QUEEN KAAHUMANU HWY, SUITE 102, KAILUA-KONA, HI 96740
    Item 2.
     (a)Name of Person Filing
    Wells Fargo & Company
     (b)Address of Principal Business Office or, if none, Residence
    420 Montgomery Street, San Francisco, CA 94163
     (c)Citizenship
    Delaware
     (d)Title of Class of Securities
    COM PAR $0.02
     (e)CUSIP Number
    232437301
     
    Item 3.If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c)
    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940
    (15 U.S.C 80a-8).
    (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g) [X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act
    (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under section
    3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] A non-U.S.institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K).
    If filing as a non-U.S.institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________
     
    Item 4.Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned:  18
     (b) Percent of class:  0.00%
     (c)Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote 18
      (ii) Shared power to vote or to direct the vote  0
       (iii) Sole power to dispose or to direct the disposition of 18
       (iv) Shared power to dispose or to direct the disposition of 0
     
     
    Item 5.Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.[X ].
     
    Item 6.Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
    See Exhibit B
    Item 8. Identification and Classification of Members of the Group
    Not applicable.
    Item 9.Notice of Dissolution of Group
    Not applicable.
    Item 10.Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    March 10, 2021
    Date
    /s/ Patricia Arce
    Signature
    Patricia Arce, Designated Signer
    Name/Title
    Exhibit A
    EXPLANATORY NOTE

    This Schedule 13G is filed by Wells Fargo & Company on its own behalf and on behalf of any subsidiaries listed in Exhibit B. Aggregate beneficial ownership reported by Wells Fargo & Company under Item 9 on page 2 is on a consolidated basis and includes any beneficial ownership separately reported herein by a subsidiary.
    Exhibit B
    The Schedule 13G to which this attachment is appended is filed by Wells Fargo & Company on behalf of the following subsidiaries:

    Wells Fargo Bank, National Association (1)

    (1) Classified as a bank in accordance with Regulation 13d-1(b)(1)(ii)(B).

     

     

    Attention:Intentional misstatements or omissions of fact constitute Federal criminal violations
    (See 18 U.S.C. 1001)
    Get the next $CYAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    SEC Filings

    See more
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      5/8/25 3:56:11 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      2/11/25 4:01:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      12/16/24 1:53:10 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Financials

    Live finance-specific insights

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by VP of Sales Brand Jennifer Kimberly

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:06:36 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, HR, Secretary Nordin Amy Beth

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:04:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, Operations Jensen Glenn

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:02:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      10/3/24 6:39:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/12/24 12:25:52 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/6/24 12:45:58 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/3/24 3:27:06 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/1/24 4:42:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/27/24 1:33:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care